Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Clinical Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Nitroxoline (Primary) ; Epirubicin
- Indications Bladder cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms ACCRUE; ACCRUE-1
- Sponsors Asieris Pharmaceuticals; Jiangsu Yahong Pharmaceutical Technology
- 07 Feb 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (Last verified Feb 2022)
- 22 Aug 2023 According to an Asieris Pharmaceuticals media release, upon reaching the predefined target number of events of this study, subsequent phases, including database lock, unbinding, and statistical analysis, will be promptly initiated.
- 21 Jun 2021 Planned End Date changed from 30 Dec 2020 to 30 May 2022.